Immunotherapy for hepatocellular carcinoma: A promising therapeutic option for advanced disease.
Hepatocellular Carcinoma
Hepatocellular Carcinoma management
Hepatocellular Carcinoma therapy
Immunotherapy
Molecular targeted therapy
Journal
World journal of hepatology
ISSN: 1948-5182
Titre abrégé: World J Hepatol
Pays: United States
ID NLM: 101532469
Informations de publication
Date de publication:
27 Oct 2022
27 Oct 2022
Historique:
received:
04
07
2022
revised:
20
07
2022
accepted:
03
10
2022
entrez:
7
11
2022
pubmed:
8
11
2022
medline:
8
11
2022
Statut:
ppublish
Résumé
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide, and its incidence continues to increase. Despite improvements in both medical and surgical therapies, HCC remains associated with poor outcomes due to its high rates of recurrence and mortality. Approximately 50% of patients require systemic therapies that traditionally consist of tyrosine kinase inhibitors. Recently, however, immune checkpoint inhibitors have revolutionized HCC management, providing new therapeutic options. Despite these major advances, the different factors involved in poor clinical responses and molecular pathways leading to resistance following use of these therapies remain unclear. Alternative strategies, such as adoptive T cell transfer, vaccination, and virotherapy, are currently under evaluation. Combinations of immunotherapies with other systemic or local treatments are also being investigated and may be the most promising opportunities for HCC treatment. The aim of this review is to provide updated information on currently available immunotherapies for HCC as well as future perspectives.
Identifiants
pubmed: 36340753
doi: 10.4254/wjh.v14.i10.1862
pmc: PMC9627435
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1862-1874Informations de copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: All the authors declare that they have no conflict of interest.
Références
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Dig Liver Dis. 2010 Jul;42 Suppl 3:S206-14
pubmed: 20547305
Clin Cancer Res. 2019 Apr 1;25(7):2116-2126
pubmed: 30373752
Nat Med. 2001 Jul;7(7):781-7
pubmed: 11433341
Med Hypotheses. 2006;66(6):1115-20
pubmed: 16504415
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Nat Rev Gastroenterol Hepatol. 2018 Sep;15(9):555-567
pubmed: 29844586
Cell. 2019 Mar 7;176(6):1248-1264
pubmed: 30849371
PLoS One. 2011;6(9):e24671
pubmed: 21935436
Oncotarget. 2015 Dec 1;6(38):41339-49
pubmed: 26515587
Lancet Oncol. 2022 Jan;23(1):77-90
pubmed: 34914889
Int J Mol Sci. 2021 May 28;22(11):
pubmed: 34071550
Hepatology. 2014 Apr;59(4):1415-26
pubmed: 24002931
JCI Insight. 2016 Jun 16;1(9):e85974
pubmed: 27699271
Int J Cancer. 2010 May 1;126(9):2164-74
pubmed: 19739081
Oncotarget. 2016 Aug 9;7(32):52294-52306
pubmed: 27418133
J Immunol. 2011 May 15;186(10):5549-55
pubmed: 21460203
Oncology. 2011;81(5-6):281-90
pubmed: 22133996
Lancet Oncol. 2018 Jul;19(7):940-952
pubmed: 29875066
Nat Med. 2013 Mar;19(3):329-36
pubmed: 23396206
J Hepatol. 2017 Mar;66(3):545-551
pubmed: 27816492
Oncotarget. 2016 Feb 9;7(6):7207-15
pubmed: 26769852
J Hepatol. 2015 Mar;62(3):607-16
pubmed: 25450711
Mol Ther. 2019 Aug 7;27(8):1483-1494
pubmed: 31078430
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
Cancers (Basel). 2022 Apr 15;14(8):
pubmed: 35454921
Cancer Res. 2009 Oct 15;69(20):8067-75
pubmed: 19826049
World J Gastroenterol. 2019 Jul 7;25(25):3136-3150
pubmed: 31333307
Cancer Immunol Immunother. 2003 Mar;52(3):155-61
pubmed: 12649744
J Gastroenterol Hepatol. 1999 May;14 Suppl:S32-6
pubmed: 10382636
J Transl Med. 2014 Apr 05;12:86
pubmed: 24708667
Hepatology. 2015 Aug;62(2):481-95
pubmed: 25833323
Oncotarget. 2017 May 23;8(21):34387-34397
pubmed: 28415739
Gastroenterology. 2015 Jun;148(7):1383-91.e6
pubmed: 25747273
J Clin Oncol. 2007 Jun 20;25(18):2586-93
pubmed: 17577038
Hepatology. 2010 Jul;52(1):360-9
pubmed: 20578152
J Hepatol. 2017 Sep 18;:
pubmed: 28923358
Oncoimmunology. 2012 Jan 1;1(1):48-55
pubmed: 22720211
Cancers (Basel). 2020 Oct 04;12(10):
pubmed: 33020428
Oncoimmunology. 2016 Jan 19;5(5):e1129483
pubmed: 27467945
Hepatology. 2021 Jan;73 Suppl 1:4-13
pubmed: 32319693
Front Immunol. 2015 Feb 25;6:49
pubmed: 25767469
Int J Mol Sci. 2022 Feb 11;23(4):
pubmed: 35216137
Rom J Morphol Embryol. 2014;55(4):1287-93
pubmed: 25611258
Transpl Int. 2022 Mar 23;35:10412
pubmed: 35401038
J Exp Med. 2009 Jun 8;206(6):1327-37
pubmed: 19451266
Minerva Surg. 2022 Aug;77(4):368-379
pubmed: 35332767
Cancer Res. 1999 Jul 1;59(13):3134-42
pubmed: 10397256
Int J Cancer. 2009 Oct 1;125(7):1640-8
pubmed: 19569243
Lancet. 2000 Sep 2;356(9232):802-7
pubmed: 11022927
Hum Vaccin Immunother. 2014;10(4):970-6
pubmed: 24419174
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
JAMA Oncol. 2020 Nov 01;6(11):e204564
pubmed: 33001135
Cancer Immunol Immunother. 2013 Aug;62(8):1421-30
pubmed: 23764929
Ann Oncol. 2018 May 1;29(5):1312-1319
pubmed: 29554212
J Clin Oncol. 2020 Sep 10;38(26):2960-2970
pubmed: 32716739
Cancer Res. 2005 Mar 15;65(6):2457-64
pubmed: 15781662
J Immunol. 2005 May 1;174(9):5215-23
pubmed: 15843517
Gastroenterology. 2016 Jun;150(7):1646-1658.e17
pubmed: 26924089
BMC Cancer. 2019 May 31;19(1):523
pubmed: 31151419
J Immunol. 2001 Jun 15;166(12):7282-9
pubmed: 11390478
J Clin Invest. 2013 Nov;123(11):4859-74
pubmed: 24216477
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
J Clin Oncol. 2009 Mar 20;27(9):1485-91
pubmed: 19224838
Cell Mol Immunol. 2017 Oct;14(10):819-829
pubmed: 27321064
World J Gastroenterol. 2006 Dec 14;12(46):7413-20
pubmed: 17167827
Clin Cancer Res. 2012 Jul 1;18(13):3686-96
pubmed: 22577059
J Immunother. 2013 Jun;36(5):287-93
pubmed: 23719239
Oncoimmunology. 2018 Jul 23;7(10):e1488564
pubmed: 30288355
Annu Rev Immunol. 2009;27:147-63
pubmed: 19302037
J Immunother. 2016 May;39(4):181-7
pubmed: 27070449
Int J Cancer. 2013 Dec 15;133(12):2895-902
pubmed: 23749461
Immunobiology. 2020 Jan;225(1):151850
pubmed: 31522780
J Hepatol. 2008 Dec;49(6):946-54
pubmed: 18619700
J Immunol. 2017 Jan 1;198(1):31-39
pubmed: 27994166
Hepatology. 2018 Sep;68(3):1025-1041
pubmed: 29603348
Gastroenterology. 2007 Jun;132(7):2557-76
pubmed: 17570226
Annu Rev Pathol. 2017 Jan 24;12:153-186
pubmed: 27959632
Cancer. 2019 Oct 15;125(20):3603-3614
pubmed: 31251403
Ann Surg Oncol. 2016 Dec;23(Suppl 5):574-582
pubmed: 26786094
Cancer Lett. 2015 Dec 1;369(1):242-9
pubmed: 26325606
Oncoimmunology. 2019 Jun 3;8(8):1615817
pubmed: 31413923
Cancer Immunol Immunother. 2016 Jan;65(1):93-9
pubmed: 26093657
Dig Liver Dis. 2009 Jan;41(1):36-41
pubmed: 18818130
Cancers (Basel). 2019 Sep 10;11(9):
pubmed: 31510063
Hepatology. 2013 Apr;57(4):1448-57
pubmed: 23174905
Nat Rev Dis Primers. 2021 Jan 21;7(1):6
pubmed: 33479224
Science. 2015 Apr 3;348(6230):62-8
pubmed: 25838374
J Biomed Res. 2018 Sep 29;32(5):317-326
pubmed: 28866656
Nat Rev Gastroenterol Hepatol. 2021 Aug;18(8):525-543
pubmed: 33850328
Ther Adv Med Oncol. 2019 Jul 23;11:1758835919862692
pubmed: 31384311
Hepatology. 2004 Dec;40(6):1312-21
pubmed: 15565659